| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 7 analysts shared their evaluations of Acadia Healthcare Co (NASDAQ:ACHC), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 1 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.86, a high estimate of $31.00, and a low estimate of $20.00. This current average represents a 27.89% decrease from the previous average price target of $35.86.
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joanna Gajuk | B of A Securities | Lowers | Neutral | $25.00 | $27.00 |
| John Ransom | Raymond James | Lowers | Outperform | $26.00 | $40.00 |
| Ann Hynes | Mizuho | Lowers | Neutral | $22.00 | $32.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $28.00 | $43.00 |
| Andrew Mok | UBS | Lowers | Buy | $31.00 | $45.00 |
| Jason Cassorla | Guggenheim | Lowers | Buy | $29.00 | $36.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $20.00 | $28.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Acadia Healthcare Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Acadia Healthcare Co analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Acadia Healthcare Co showcased positive performance, achieving a revenue growth rate of 9.19% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Acadia Healthcare Co's net margin is impressive, surpassing industry averages. With a net margin of 3.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Acadia Healthcare Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.48%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.78, Acadia Healthcare Co adopts a prudent financial strategy, indicating a balanced approach to debt management.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ACHC
